ES2545906T3 - (2R)-enantiómero de cloruro de DOTAP - Google Patents

(2R)-enantiómero de cloruro de DOTAP Download PDF

Info

Publication number
ES2545906T3
ES2545906T3 ES05802304.5T ES05802304T ES2545906T3 ES 2545906 T3 ES2545906 T3 ES 2545906T3 ES 05802304 T ES05802304 T ES 05802304T ES 2545906 T3 ES2545906 T3 ES 2545906T3
Authority
ES
Spain
Prior art keywords
enantiomer
dotap chloride
chloride
dotap
dioleoyloxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES05802304.5T
Other languages
English (en)
Inventor
Michael Platscher
Alfred Hedinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Application granted granted Critical
Publication of ES2545906T3 publication Critical patent/ES2545906T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/08—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to an acyclic carbon atom of an acyclic unsaturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Cloruro de (2R)-1,2-dioleoiloxi-3-trimetilamoniopropano (cloruro de (2R)-DOTAP) enantioméricamente puro.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7

Claims (1)

  1. imagen1
ES05802304.5T 2004-11-26 2005-11-07 (2R)-enantiómero de cloruro de DOTAP Active ES2545906T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004057303 2004-11-26
DE102004057303A DE102004057303A1 (de) 2004-11-26 2004-11-26 Stabile Kristallmodifikationen von DOTAP Chlorid
PCT/EP2005/011874 WO2006056312A1 (de) 2004-11-26 2005-11-07 Stabile kristallmodifikationen von dotap chlorid

Publications (1)

Publication Number Publication Date
ES2545906T3 true ES2545906T3 (es) 2015-09-16

Family

ID=35789283

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05802304.5T Active ES2545906T3 (es) 2004-11-26 2005-11-07 (2R)-enantiómero de cloruro de DOTAP

Country Status (21)

Country Link
US (2) US8853283B2 (es)
EP (1) EP1814843B1 (es)
JP (1) JP4880612B2 (es)
KR (1) KR101249370B1 (es)
CN (2) CN102796016B (es)
AU (1) AU2005309107B2 (es)
BR (2) BR122019018186B8 (es)
CA (1) CA2589218C (es)
DE (1) DE102004057303A1 (es)
ES (1) ES2545906T3 (es)
HK (1) HK1178143A1 (es)
HU (1) HUE027554T2 (es)
IL (1) IL183324A (es)
MX (1) MX2007006128A (es)
NO (1) NO338885B1 (es)
NZ (2) NZ582382A (es)
PL (1) PL1814843T3 (es)
PT (1) PT1814843E (es)
RU (1) RU2463291C2 (es)
WO (1) WO2006056312A1 (es)
ZA (1) ZA200705169B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
US7303881B2 (en) * 2004-04-30 2007-12-04 Pds Biotechnology Corporation Antigen delivery compositions and methods of use
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US8877206B2 (en) * 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
WO2009129227A1 (en) * 2008-04-17 2009-10-22 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
SG10201706859QA (en) 2011-05-20 2017-09-28 Merck Patent Gmbh Stable crystal modifications of dotap chloride
CA2836494C (en) 2011-05-24 2023-01-03 Biontech Ag Individualized vaccines for cancer
ES2689799T3 (es) * 2011-09-12 2018-11-15 Pds Biotechnology Corporation Formulaciones de vacunas particuladas
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
TWI672149B (zh) 2012-09-21 2019-09-21 美商Ｐｄｓ生技公司 改良之疫苗組成物及使用方法
US10155031B2 (en) 2012-11-28 2018-12-18 Biontech Rna Pharmaceuticals Gmbh Individualized vaccines for cancer
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
WO2017083820A1 (en) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
DE4013632A1 (de) * 1990-04-27 1991-10-31 Max Planck Gesellschaft Liposomen mit positiver ueberschussladung
DE19521412A1 (de) * 1995-06-14 1996-12-19 Boehringer Mannheim Gmbh Neue kationische und polykationische Amphiphile, diese enthaltende Reagenzien und deren Verwendung
JP2000509404A (ja) * 1996-05-08 2000-07-25 ニカ ヘルス プロダクツ リミテッド 遺伝物質の導入システムとしてのカチオン性ヴィロソーム
EP1254657B1 (en) * 1996-09-13 2008-05-21 Lipoxen Technologies Limited Liposomes
US6458382B1 (en) * 1999-11-12 2002-10-01 Mirus Corporation Nucleic acid transfer complexes
ES2183720B1 (es) 2001-06-18 2004-01-16 Esteve Labor Dr Procedimiento para la preparacion de derivados de 1,5-diaril-3-trifluorometil-delta2-pirazolinas racemicas y enantiomericamente puras.
ITMI20032185A1 (it) * 2003-11-12 2005-05-13 Chemi Spa Processo per la sintesi di lipidi cationici.

Also Published As

Publication number Publication date
NZ556060A (en) 2010-03-26
IL183324A0 (en) 2007-09-20
WO2006056312A1 (de) 2006-06-01
BRPI0518489B8 (pt) 2021-05-25
NO338885B1 (no) 2016-10-31
RU2463291C2 (ru) 2012-10-10
DE102004057303A1 (de) 2006-06-01
BRPI0518489B1 (pt) 2020-03-31
CN101065350A (zh) 2007-10-31
NZ582382A (en) 2010-08-27
HK1178143A1 (zh) 2013-09-06
CA2589218C (en) 2013-12-17
CN102796016A (zh) 2012-11-28
US20140370081A1 (en) 2014-12-18
CN102796016B (zh) 2015-09-02
EP1814843A1 (de) 2007-08-08
PL1814843T3 (pl) 2015-11-30
NO20073286L (no) 2007-06-25
KR20070084501A (ko) 2007-08-24
US8853283B2 (en) 2014-10-07
BR122019018186B8 (pt) 2021-07-27
MX2007006128A (es) 2007-07-13
IL183324A (en) 2013-10-31
EP1814843B1 (de) 2015-06-24
PT1814843E (pt) 2015-10-13
BR122019018186B1 (pt) 2021-03-09
US20080014254A1 (en) 2008-01-17
JP4880612B2 (ja) 2012-02-22
AU2005309107A1 (en) 2006-06-01
HUE027554T2 (en) 2016-10-28
KR101249370B1 (ko) 2013-04-01
AU2005309107B2 (en) 2011-07-21
ZA200705169B (en) 2008-08-27
RU2007123673A (ru) 2009-01-10
BRPI0518489A2 (pt) 2008-11-25
JP2008521757A (ja) 2008-06-26
US9457087B2 (en) 2016-10-04
CA2589218A1 (en) 2006-06-01

Similar Documents

Publication Publication Date Title
ES2545906T3 (es) (2R)-enantiómero de cloruro de DOTAP
DE602005010109D1 (de) 1,1a,5,5a-tetrahydro-3-thia-cyclopropaäaüpentaleneptor-agonisten
ITBO20030403A1 (it) Macchina ginnica.
ITVR20020088A1 (it) Macchina flessografica.
NL1030253A1 (nl) Elektronenmicroscoop.
ITMO20030081A0 (it) Bioreattore,particolarmente per organi bioartificiali.
NL1024983A1 (nl) Morfolinen als dopamineagonisten.
ITRA20030024A1 (it) Macchina ginnica.
NL1025769A1 (nl) Projectiesysteem.
ITRE20020073A1 (it) Macchina equilibratrice.
FR2850147B1 (fr) Support anti-vibratoire.
ITMI20032037A1 (it) Supporto del cruscotto.
ES1056425Y (es) Soporte informativo.
ES1054995Y (es) Multijuego rotativo.
ITTO20020222A1 (it) Schermo di supporto per ruota fonica.
ITFO20030011A1 (it) Paratia removibile antialluvione.
ES1055317Y (es) Escenario autotransportable.
ES1055913Y (es) Linterna.
ITMO20040317A1 (it) Dispositivo di supporto per informazioni.
ES1052333Y (es) Cajon premarco.
ITBS20030119A1 (it) Supporto per motocicli.
ITRM20030377A0 (it) Proiettore perfezionato.
ITPN20020035U1 (it) Dispositivo portabiancheria.
ITTO20020259A1 (it) Visore per diapositive stereoscopiche.
ES1051283Y (es) Portabalas multicalibres.